NEWS OF MEDICINE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

About the authors

- -

References

  1. Chen R., Zinzani P.L., Lee H.J., et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1 144-1 153. doi: 10.1182/blood.2019000324.
  2. Allen P.B., Chen Q.C., Lu X., et al. Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma: updated results and correlative analysis [ASH abstract 231]. Blood. 2021;138(suppl 1).
  3. Лимфома Ходжкина. Клинические рекомендации. Одобрено на заседании Научно-практического совета Министерства здравоохранения Российской Федерации (протокол от «10» апреля 2020 г. № 17/2-3-4).

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies